Ratings by BofA Securities (Tim Anderson)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/2/2026 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 3/2/2026 | Aardvark Therapeutics Inc | AARD | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 2/20/2026 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 2/11/2026 | Gilead Sciences | GILD | Maintain | Buy (N/A) |
|
Details | ||
| 2/11/2026 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 2/5/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 2/4/2026 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 1/26/2026 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 1/22/2026 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 1/22/2026 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 1/13/2026 | Amgen | AMGN | Maintain | Underperform (N/A) |
|
Details | ||
| 1/9/2026 | Gilead Sciences | GILD | Maintain | Underperform (N/A) |
|
Details | ||
| 1/7/2026 | Regeneron Pharma | REGN | Upgrade | Buy (Underperform) |
776.54 (759.86) |
-2.15% | Details | |
| 1/6/2026 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 12/16/2025 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 12/15/2025 | Bristol-Myers Squibb Co. | BMY | Upgrade | Buy (Neutral) |
52.41 (60.29) |
15.04% | Details | |
| 12/1/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 10/29/2025 | Regeneron Pharma | REGN | Maintain | Underperform (N/A) |
|
Details | ||
| 10/9/2025 | Apogee Therapeutics Inc | APGE | Maintain | Buy (N/A) |
|
Details | ||
| 10/3/2025 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 8/28/2025 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 8/28/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (N/A) |
|
Details | ||
| 8/28/2025 | Apogee Therapeutics Inc | APGE | Maintain | Buy (N/A) |
|
Details | ||
| 8/28/2025 | Metsera Inc | MTSR | Maintain | Buy (N/A) |
|
Details | ||
| 8/28/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Buy (N/A) |
|
Details | ||
| 8/26/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2025 | Gilead Sciences | GILD | Maintain | Buy (N/A) |
|
Details | ||
| 8/4/2025 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 7/23/2025 | Amgen | AMGN | Maintain | Underperform (N/A) |
|
Details | ||
| 4/25/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/17/2025 | Regeneron Pharma | REGN | Maintain | Underperform (N/A) |
|
Details | ||
| 4/17/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 3/27/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2025 | Aardvark Therapeutics Inc | AARD | New Coverage | Buy (N/A) |
10.13 (5.85) |
-42.25% | Details | |
| 3/3/2025 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 2/25/2025 | Metsera Inc | MTSR | New Coverage | Buy (N/A) |
29.81 (70.50) |
136.5% | Details | |
| 2/11/2025 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 2/11/2025 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 1/24/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 1/23/2025 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 1/15/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 12/10/2024 | Regeneron Pharma | REGN | New Coverage | Underperform (N/A) |
788.00 (776.54) |
-1.45% | Details | |
| 12/10/2024 | Moderna | MRNA | New Coverage | Underperform (N/A) |
45.65 (52.52) |
15.05% | Details | |
| 12/10/2024 | Gilead Sciences | GILD | New Coverage | Buy (N/A) |
90.59 (143.93) |
58.88% | Details | |
| 12/10/2024 | Biogen | BIIB | New Coverage | Neutral (N/A) |
156.46 (184.87) |
18.16% | Details | |
| 12/10/2024 | Amgen | AMGN | New Coverage | Underperform (N/A) |
277.63 (369.53) |
33.1% | Details | |
| 12/10/2024 | Pfizer | PFE | New Coverage | Neutral (N/A) |
26.10 (27.05) |
3.64% | Details | |
| 12/10/2024 | Merck | MRK | New Coverage | Buy (N/A) |
103.79 (115.79) |
11.56% | Details | |
| 12/10/2024 | Eli Lilly | LLY | New Coverage | Buy (N/A) |
803.58 (990.33) |
23.24% | Details | |
| 12/10/2024 | Johnson & Johnson | JNJ | New Coverage | Neutral (N/A) |
149.60 (240.40) |
60.7% | Details | |
| 12/10/2024 | Bristol-Myers Squibb Co. | BMY | New Coverage | Neutral (N/A) |
58.71 (52.41) |
-10.73% | Details | |
| 12/10/2024 | Abbvie | ABBV | New Coverage | Neutral (N/A) |
176.57 (230.11) |
30.32% | Details |
